A research and training program for junior clinicians in treating metastatic mela

初级临床医生治疗转移性黄斑变性的研究和培训计划

• 批准号: 9279067
• 负责人: Harriet M. Kluger
• 金额: $ 15.61万
• 依托单位: YALE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-07-01 至 2019-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9279067
• 关键词: Advisory Committees; Animal Experiments; Animals; Antibodies; Autacoids; Autopsy; Award; BRAF gene; Basic Science; Biological Assay; Biological Markers; Blood - brain barrier anatomy; Brain; Brain imaging; Central Nervous System Agents; Central Nervous System Diseases; Characteristics; Clinical; Clinical Sciences; Clinical Trials; Coupled; Cytotoxic T-Lymphocyte-Associated Protein 4; Data; Development; Development Plans; Disease; Drug Combinations; Drug Kinetics; Drug resistance; Electrocoagulation; Enrollment; Ethics; Faculty; Frequencies; Funding; Future; Gamma Knife Radiosurgery; Goals; Grant; Immunity; Immunotherapy; In Vitro; Incidence; Individual; Investigation; Laboratories; Laboratory Research; Lasers; Lesion; Local Therapy; Location; MAP Kinase Gene; Malignant Neoplasms; Mediation; Melanoma Cell; Mentors; Mentorship; Metastatic Melanoma; Metastatic malignant neoplasm to brain; Molecular Biology; Neoadjuvant Study; Neoadjuvant Therapy; Neoplasm Metastasis; Neuraxis; Oncologist; Operative Surgical Procedures; Pathway interactions; Patients; Penetration; Pharmaceutical Preparations; Pharmacodynamics; Pharmacologic Substance; Pharmacology; Population; Principal Investigator; Process; Protocols documentation; Radiosurgery; Renal Cell Carcinoma; Reporting; Research; Research Design; Research Personnel; Research Training; Resistance; Running; Sampling; Specimen; Systemic Therapy; Techniques; Technology; Therapeutic; Therapy Clinical Trials; Time; Training; Training Programs; Unresectable; Visceral; Vision; Wit; base; career development; clinical practice; design; disorder control; drug development; drug sensitivity; drug testing; experimental study; immune checkpoint; improved; inhibitor/antagonist; innovation; interstitial; lectures; material transfer agreement; melanoma; member; mid-career faculty; molecular drug target; molecular targeted therapies; mutant; novel; novel strategies; outcome forecast; patient oriented research; patient population; phase I trial; pre-clinical; predicting response; predictive marker; public health relevance; response; skills; statistics; targeted treatment; tool; translational research program; trial design; tumor

DESCRIPTION (provided by applicant): This K24 application is to support my career development as I build a translational research program. I am an associate professor, seeing patients with melanoma and renal cell carcinoma. I mentor junior faculty and clinical fellows and run an R-01 funded research laboratory, conducting biomarker studies and pre-clinical drug testing experiments in these two diseases. I have a busy clinical practice and actively enroll patients on clinical trials. Given the increased incidence of metastatic melanoma and the high frequency of brain metastases (BrMs) in this population, there is urgent need for new approaches to this problem, as most clinical trials exclude BrMs patients, and their therapeutic options are exceedingly limited. I recently assembled a group of clinical and basic science researchers that focus on BrMs, and my vision (and long term goal) is to develop a brain metastasis research center at Yale. My short term goal is to conduct our first two BrMs-specific protocols and to generate preclinical data for future trials. To accomplish my goals, I need additional protected time to conduct these studies and mentor junior clinicians to participate these efforts. My proposed career development plan includes both acquisition of new skills and a plan for increased mentorship of junior faculty and clinical fellows. The former involves formal training such as a didactic statistics course and informal training in animal experiments and additional training in development of phase I trials. In addition to mentorship of fellows, I will mentor junior faculty, including two current mentees and two new hires. I will participate in specific mentorship activities at Yale supported by the CTSA grant, including advisory committees and lectures. The underlying premise of this proposal is that drug penetration through the leaky vessels found in BrMs can be superior to typical BBB penetration. We further hypothesize that use of combinations of local therapies and molecular targeted therapies selected based on individual tumor characteristics will result in improved survival of patients wit BrMs, similar to patients with other visceral metastases. Finally, manipulation of brain immunity might be a means of treating brain metastases. My first aim includes the first neoadjuvant clinical trial using a targeted therapy (vemurafenib) and innovative surgical approaches to treat patients with brain metastases not amenable to gamma-knife therapy. Predictive biomarker studies will be incorporated, complimented by lab-based endeavors to train mentees in conducting pre-clinical drug sensitivity studies with an emphasis on BrMs, with the goal of developing a pipeline of drugs to be studied in future BrM trials. In aim 2, I will mentor a junior faculty clinician in conducting a clinical trial of an antibody against an immune-checkpoint inhibitory molecule (PD-1), and development of a panel of predictive biomarkers.

描述（由申请人提供）：这个K24应用程序是支持我的职业发展，因为我建立一个转化研究计划。我是一名副教授，治疗黑色素瘤和肾细胞癌患者。我指导初级教师和临床研究员，并运行一个R-01资助的研究实验室，在这两种疾病中进行生物标志物研究和临床前药物测试实验。我有一个忙碌的临床实践，并积极招募患者进行临床试验。鉴于转移性黑色素瘤的发病率增加和高频率的脑转移瘤（BrMs）在这一人群中，有迫切需要新的方法来解决这个问题，因为大多数临床试验排除BrMs患者，他们的治疗选择是非常有限的。我最近召集了一组临床和基础科学研究人员，专注于BRM，我的愿景（和长期目标）是在耶鲁大学建立一个脑转移研究中心。我的短期目标是进行我们的前两个BRM特定的协议，并为未来的试验产生临床前数据。为了实现我的目标，我需要额外的保护时间来进行这些研究，并指导初级临床医生参与这些工作。 我提出的职业发展计划包括获得新技能和增加初级教师和临床研究员的指导计划。前者涉及正式培训，如教学统计学课程和动物实验方面的非正式培训以及第一阶段试验开发方面的额外培训。除了指导研究员，我将指导初级教师，包括两个目前的学员和两个新员工。我将参加由CTSA资助的耶鲁大学的具体导师活动，包括咨询委员会和讲座。 该提议的基本前提是，药物通过在BrMs中发现的渗漏血管的渗透可以上级典型的BBB渗透。我们进一步假设，基于个体肿瘤特征选择的局部治疗和分子靶向治疗的组合使用将导致BrM患者的生存率提高，与其他内脏转移患者相似。最后，操纵脑免疫可能是治疗脑转移瘤的一种手段。我的第一个目标包括第一个新辅助临床试验，使用靶向治疗（vemurafenib）和创新的手术方法来治疗不适合伽玛刀治疗的脑转移患者。预测性生物标志物研究将被纳入，并辅以基于实验室的努力，以培训学员进行临床前药物敏感性研究，重点是BrM，目标是开发一个在未来BrM试验中研究的药物管道。在目标2中，我将指导一名初级 在进行针对免疫检查点抑制分子（PD-1）的抗体的临床试验，并开发一组预测性生物标志物方面，

项目成果

Driver mutations in melanoma: lessons learned from bench-to-bedside studies.

• DOI: 10.1007/s11912-012-0249-5
• 发表时间: 2012-10
• 期刊: CURRENT ONCOLOGY REPORTS
• 影响因子: 4.7
• 作者: Mehnert, Janice M.;Kluger, Harriet M.
• 通讯作者: Kluger, Harriet M.

Melanoma Brain Metastasis Pseudoprogression after Pembrolizumab Treatment.

pembrolizumab治疗后黑色素瘤脑转移伪孕期。

• DOI: 10.1158/2326-6066.cir-15-0160
• 发表时间: 2016-03
• 期刊: Cancer immunology research
• 影响因子: 10.1
• 作者: Cohen JV;Alomari AK;Vortmeyer AO;Jilaveanu LB;Goldberg SB;Mahajan A;Chiang VL;Kluger HM
• 通讯作者: Kluger HM

From the Guest Editors: Recent Advances and Evolving Challenges in Treating Unresectable Melanoma.

来自客座编辑：治疗不可切除黑色素瘤的最新进展和不断变化的挑战。

• DOI: 10.1097/ppo.0000000000000244
• 发表时间: 2017
• 期刊: Cancer journal (Sudbury, Mass.)
• 作者: Weiss,SarahA;Kluger,HarrietM
• 通讯作者: Kluger,HarrietM

Systemic Immunotherapy for the Treatment of Brain Metastases.

• DOI: 10.3389/fonc.2016.00049
• 发表时间: 2016
• 期刊: Frontiers in oncology
• 影响因子: 4.7
• 作者: Cohen JV;Kluger HM
• 通讯作者: Kluger HM

Nivolumab plus ipilimumab in advanced melanoma.

• DOI: 10.1056/nejmoa1302369
• 发表时间: 2013-07-11
• 期刊: The New England journal of medicine
• 作者: Wolchok JD;Kluger H;Callahan MK;Postow MA;Rizvi NA;Lesokhin AM;Segal NH;Ariyan CE;Gordon RA;Reed K;Burke MM;Caldwell A;Kronenberg SA;Agunwamba BU;Zhang X;Lowy I;Inzunza HD;Feely W;Horak CE;Hong Q;Korman AJ;Wigginton JM;Gupta A;Sznol M
• 通讯作者: Sznol M